替莫唑胺治疗复发脑胶质瘤效果分析

目的探讨替莫唑胺(Temozolomide,TMZ)治疗复发脑胶质瘤的临床效果与安全性。方法选择复发脑胶质瘤42例口服TMZ起始剂量150 mg/(m2·d),连服5 d,28 d为1个周期。治疗3个周期后观察临床效果与不良反应情况。结果本组42例均顺利完成化疗,期间无1例出现治疗相关性死亡。本组15例肿瘤明显缩小,部分缓解(PR)率为35.7%(15/42);16例肿瘤稳定,疾病稳定(SD)率为38.1%(16/42);11例肿瘤增大,进展(PD)率为26.2%(11/42)。有效率(CR+PR)为35.7%(15/42),疾病控制率(CR+PR+SD)为73.8%(31/42)。本组21例出现恶心、呕吐症状,6例出现白细胞、中性粒细胞、血小板降低等毒性反应,2例出现不同程度脱发,但均未发生肝、肾、肺等其他重要脏器损的害。结论 TMZ对复发脑胶质瘤具有一定的临床效果,其不良反应少,是较理想的化疗用药。

Efficacy Analysis of Temozolomide in Treatment of Recurrent Brain Glioma

Objective To evaluate the efficacy and safety of temozolomide （ TMZ） in the treatment of recurrent brain gliomas. Methods A total of 42 patients with recurrent brain glioma were treated by TMZ with a initial dosage of 150 mg/m2 once a day for durative 5 days and 28 days as a treatment cycle. The clinical curative effect and complications were observed after 3 cycles of treatment. Results The group of 42 patients was successfully completed chemotherapy, and no treatment-re-lated death occurred during the therapy. There were 15 patients with reduced tumor sizes, and the partial remission （ PR） rate was 35.7% （15/42）; 16 patients with stable diseases, and the stable disease （stable disease, SD） rate was 38. 1%（16/42）;11 patients with tumor growth, and the progression （progressive disease, PD） rate was 26. 2% （11/42）. Efficien-cy rate （CR＋PR） in the group was 35. 7% （15/42）, and disease control rate （CR＋PR＋SD） was 73. 8% （31/42）. Twenty-one patients had nausea and vomiting, and six patients had toxic reactions, such as decreased white blood cells, neu-trophils, and platelets. Two patients showed different degrees of hair loss, but no damage of liver, kidney, and lung. Conclu-sion TMZ is an ideal chemotherapy drug that can be used to treat recurrent brain glioma, because it has a certain clinical effect and less adverse reaction.